Orchid Pharma Limited · NSE:ORCHPHARMA
Orchid Pharma — Non-Deal Roadshow (June 2021)
30 slides from Orchid Pharma's roadshow presentation, Jun 16, 2021
Slide 1: Orchid Pharma regulatory intimation letter for investor presentation
OrchidPharmaY ( Formerly known as Orchid Chemicals & Pharmaceuticals Limited } Corp. Off.: Orchid Pharma Ltd., ‘Orchid Towers’ 313, Valluvarkottam High Road, Nungambakkam, Chennai - 600 034. India CIN: L24222TN1992PLC022994 June 16, 2021 National Stock Exchange of India Ltd BSE Limited Listing Depar
Slide 2: The Turnaround Story
OrchidPharma? — A Dhanuka Group Co The Turnaround Story
Slide 3: Disclaimer
OrchidPharma¥ A Dhanuka Group Company DISCLAIMER This presentation has been prepared by Orchid Pharma Limited (the “Company”) solely for your information and for your use and may not be taken away, distributed, reproduced, or redistributed or passed on, directly or indirectly, to any other person (w
Slide 4: Company Overview
OrchidPharma? A Dhanuka Group Company COMPANY OVERVIEW PIONEER IN CEPHALOSPORIN ANTIBIOTICS R&D Focused, Inventor of Enmetazobactam (Ph.-3 Trials done in US & EU) Acquired by Dhanuka Group through CIRP Process on 1st April 2020 ABOUT DHANUKA GROUP ~ 2500 Crore diversified group. interests in Crop Ca
Slide 5: Company history and milestones
OrchidPharma? — A Dhanuka Group Company — -0e@ e @e- @ 1992 @ 2021 Orchid was Formed Marked Improvement in Performance 6°” @ 2020 First USFDA Approval Dhanuka Acquires Orchid on 31st March 2020 FDF Facility Inaugurated by Dr. APJ Abdul Kalam @ 2008 @ 2019 First ANDA Approval NCLT Approves Dhanuka’s
Slide 6: Background and Pedigree
Orchids OrchidPharma? BACKGROUND AND PEDIGREE -0e@ @ee- DHANUKA AGRITECH LTD DHANUKA LABORATORIES LTD. ¢ Flagship of the Group founded in 1980. 4 * Pharmaceutical Arm started in 1998. EN ¢ Listed on Stock Exchanges for 35 years with a Market ¢ Leader in Cephalosporin Antibiotics in Emerging markets.
Slide 7: Key Rationale for Acquiring Orchid Pharma
OrchidPharma? — A Dhanuka Group Company — KEY RATIONALE FOR ACQUIRING ORCHID PHARMA -0e@ e @e- ORCHID DHANUKA GROUP Strengths 1. Regulatory Approvals— US / EU / Strengths Japan / LATAM 1. Cost Efficient Management 2. Large Capacity 2. strong R&D wee 3. Widest Range 3. Execution Capabilities Threats
Slide 8: Antibiotics - The Life Saving Drugs
OrchidPharma¥ — A Dhanuka Group Company — ANTIBIOTICS - THE LIFE SAVING DRUGS GLOBAL ANTIBIOTICS MARKET SHARE, BY DRUGS CLASS,2019% > Global Antibiotics Market in 2019 — USD 43 bn EO Cephalosporin sascnncncnnncecn sc scnnenceenscnnencnenncecnscscnnennnansnnnnnanannannnansannnansanansnnsnsanananennan
Slide 9: Capabilities
OrchidPharma? — A Dhanuka Group Company CAPABILITIES
Slide 10: Widest Range of Cephalosporins
OrchidPharma — A Dhanuka Group Company — WIDEST RANGE OF CEPHALOSPORINS GENERATION 4 ORAL ORAL * Cefadroexil ORAL Cefprozil * Cefalexin Cefdinir Cefuroxime STERILE * Cefradine Cefditoren Cefepime Cefixime STERILE STERILE Cefpirome STERILE Cefpodoxime Cefoxitin Cefquinome Ceftobiprole * Cefalonium Ce
Slide 11: Global Presence with a Wide Customer Base
OrchidPharma¥ — A Dhanuka Group Company — GLOBAL PRESENCE WITH A WIDE CUSTOMER BASE KUKJEPHARMA v ORCHID’S PRESENCE SANDOZ (i/Mylan hikma. ‘at —) Pfizer oH Mm» . D> olpharma te e Otsuka Momenta ww POP eal SANOFl eg- 9 , —_L STADA sen PHARMA Revenue Breakup by Geography Export Market Share by Geograp
Slide 12: Largest Integrated Cephalosporin API Company
Pharma? LARGEST INTEGRATED CEPHALOSPORIN API COMPANY ¢ Integrated facilities from Intermediate to finished — 60 Acre ¢ Sterile — 3 Lines Sterile Crystalline and 1 Lyophilized ¢ Oral—7 Blocks with multiple lines ¢ Intermediates — 5 Blocks with multiple lines ¢ Total Capacity 9OOMT ¢ Worldwide approva
Slide 13: Finished Dosage Facilities
OrchidPharma? — A Dhanuka Group Company — FINISHED DOSAGE FACILITIES "Ie IKKT ¢ USFDA / UKMHRA Certified ¢ 29 ANDAs with associated DMFs ¢ Exporting to US / EU Markets ¢ Now Hived off to associate JV Company ire ‘chid Pharma Ltd) Fl ¢ Was a small Cephalosporin Operation ¢ Now being upgraded to meet
Slide 14: Strong R&D Capabilities
Pharma’ STRONG R&D CAPABILITIES ANALYTICAL R&D PROCESS R&D Sterile Crystallization & Lyophilization Chemical Resolution Amino acids and peptide synthesis ay ORCHID PHARMA HAS BEEN FOCUSED ON R&D, WILL
Slide 15: Board of Directors
OrchidPharma¥ — A Dhanuka Group Company — -0@ eo @e- BOARD OF DIRECTORS Mr. Ram Gopal Agarwal Mr. Manish Dhanuka Mr. Arun Kumar Dhanuka Mr. Mridul Dhanuka Chairman and Non- Managing Director Non-Executive Director Whole-Time Director Executive Director ~Visionary Leader at the ~Director at DLL, DAL
Slide 16: Focus on ESG
OrchidPharma¥ — A Dhanuka Group Company — FOCUS ON ESG Environment Consciousness has been Orchid's Of. Hallmark right from Inception. Dupont safety systems implemented with an aim 02 ; of Zero Incident 03 Orchid now backed by Dhanuka group, having TARA excellent Corporate Governance Standards ORCHID
Slide 17: Commitment to Environment
OrchidPharma? COMMITMENT TO ENVIRONMENT AIR ¢ Advanced Evaporation and RO Systems ¢ Vent Gas Scrubbing System * ZERO Liquid Discharge * Highest Possible Recovery @ -80deg Centigrade « No fugitive Emissions * 70% of fresh Water is recycled after recovery ¢ ESP / Venturi Filters for Particle Arrest
Slide 18: Future Strategy
OrchidPharma? — A Dhanuka Group Company — FUTURE STRATEGY
Slide 19: Strategy for Orchid API Business
OrchidPharma? — A Dhanuka Group Company — STRATEGY FOR ORCHID API BUSINESS WIN BACK LOST BUSINESS GROW NEW BUSINESS DEBT REDUCTION ¢ Bring down term debt to below * ORAL * To develop new products, which Rs. 100 crore by March 2022 * Target old customers in ele already off patent, but notin * Hiving
Slide 20: Strategy - To Attain Leadership in APIs
OrchidPharmar — A Dhanuka Group Company — STRATEGY - TO ATTAIN LEADERSHIP IN APIS * Business Consolidation Committee formed to evaluate the consolidation of Dhanvuka Laboratories Limited with Orchid. PROPOSALTO CONSOLIDATE GROUP’S API * This consolidation was part of the Resolution Plan suomitted to
Slide 21: Proud Moment for India
OrchidPharma? — A Dhanuka Group Company — PROUD MOMENT FOR INDIA mo SPee Pee ws Pia I Oi FIRST PRODUCT INVENTED IN INDIA, TO CLEAR PH.-3 In 2013, Orchid out licensed a NCE Enmetazobactum to Allecra Therapeutics, Germany for Clinical Trials. Cleared the Phase 3 trials in October 2020. This is a Uniqu
Slide 22: Financials
OrchidPharma¥ FINANCIALS
Slide 23: Impact of COVID-19
OrchidPharma? — A Dhanuka Group Company — IMPACT OF COVID-19 COVID - 19 created Estimated demand In last one year of our takeover, we havoc across the reduction of ~ 20% in have utilized the spare capacity to Pharmaceutical 2020 vs 2019. complete validation batches of supply chain new product filing
Slide 24: Cost Control Measures Improving Financial Performance
OrchidPharma? ~ COST CONTROL MEASURES IMPROVING FINANCIAL PERFORMANCE -0e@ e @e- IMPROVING PROFITABILITY... ORCHID FINANCIALS PRODUCT-MARKET MIX 600 — 481451 N m Regulated - Oral 400 m= Regulated - Sterile 200 —., = Emerging - Oral ; 9 ] m= Emerging - Sterile m 19-20 m 20-21 Sales EBITDA ...AS A RES
Slide 25: Slide 25
Slide 26: Financial Performance (Excluding IKKT Business)
OrchidPharma? — A Dhanuka Group Company — FINANCIAL PERFORMANCE (EXCLUDING IKKT BUSINESS) -©@@ee- (Rs Crs) FY2021 FY2020 Change % Sales 450.70 481.21 -6.34% Other Income!) 6.48 24.28 COGS 229.27 200.31 Employee Expenses 64.40 71.60 Other Expenses 99.14 199.97 EBIDTA (including other income)* 63.64 9
Slide 27: Slide 27
Slide 28: Current Shareholding of Orchid Pharma Ltd.
OrchidPharma — A Dhanuka Group Company — Current Corporate Structure Dhanuka Group Dhanuka Laboratories Ltd. Public Dhanuka Agritech Ltd. (Unlisted) Public & Others Current Shareholding of Orchid Pharma Ltd. SH Summary (%) No. of Shares Holding (%) Promoters 4,00,15,963 98.04% Financial Institutions
Slide 29: CSR Initiatives
OrchidPharma? — A Dhanuka Group Company — CSR INITIATIVES As a global pharmaceutical corporation, company's desire to cure extends beyond health care, spilling over to ills in the social and economic arenas This sensitivity to the community related issues has spurred into creating a development trus
Slide 30: Awards and Accolades
Pharma ; —A Group Company — AWARDS AND ACCOLADES > ai Top Indian Public Limited Company in Patent at the 5th National Intellectual Received EXIM Achievement Award 2012 Property Award 2013, for its meritorious export performance by organized by Cll The Tamil Chamber of Commerce, Chennai J > D (eee e